Mercury Pharmaceuticals

14

Sep 2026

More data, more answers? A 1.9 million-person health study shows why scale has limits

Researchers analyzed phenotypic and linked health-record data from more than 1.9 million adults in Our Future Health, comparing demographic characteristics, disease patterns, clinical associations, and rare-condition case counts with national data and other major cohorts. The cohort's size provides unusually large samples for many common and less common conditions, although its demographic composition and current data sources require careful consideration when interpreting population-level estimates.

READ MORE

14

Sep 2026

APOE genotype helps p-tau217 predict who may develop cognitive impairment sooner

A pooled analysis of 8,582 adults from seven prospective cohorts found that higher plasma p-tau217 concentrations were associated with greater cognitive impairment risk and earlier progression, with stronger associations among APOE-ε4 carriers. Each 1-SD increase in p-tau217 was associated with a 24% shorter time to cognitive impairment among carriers compared with 13% among non-carriers, suggesting that genetic background can refine the prognostic meaning of this Alzheimer’s disease blood biomarker.

READ MORE

13

Sep 2026

A study of ayahuasca users found a mental health pattern researchers cannot yet explain

In a cross-sectional study of 808 Brazilian adults planning to attend ayahuasca ceremonies, greater prior experience with the brew was associated with lower depression, anxiety, and stress scores, as well as higher spiritual well-being and stronger metaphysical beliefs. Because the study was observational and relied on self-reported data, it cannot show that ayahuasca caused these differences.

READ MORE

13

Sep 2026

Cockroaches have a reputation for surviving almost anything, but this diet proved deadly

A laboratory study tested how ultra-processed, unprocessed, and mixed diets affected survival in 127 lobster cockroaches, <em>Nauphoeta cinerea</em>. Cockroaches fed only ultra-processed foods had higher mortality than those given unprocessed or mixed diets, although the study could not determine whether processing, ingredients, nutrition, or differences in food intake caused the effect.

READ MORE

13

Sep 2026

A large US study found no overall link between fluoride in pregnancy and children’s behavior

A US cohort study of 5,520 children found no overall association between prenatal exposure to fluoride in public drinking water and internalizing or externalizing behavioral problems across the primary analyses. Exploratory analyses identified some associations with externalizing problems at higher fluoride concentrations and in certain subgroups, but the researchers said these findings require further investigation.

READ MORE

12

Sep 2026

Subcutaneous tarlatamab exhibits low toxicity rates in phase 1b trial

Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1b DeLLphi-308 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

READ MORE

12

Sep 2026

Phase 2 study highlights flexible dosing options for tarlatamab in relapsed SCLC

Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously treated for small cell lung cancer (SCLC), according to results from the randomized Phase 2 DeLLphi-309 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

READ MORE

12

Sep 2026

MD Anderson trial challenges local consolidative therapy paradigm in NSCLC

Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC), including those with oligometastatic disease, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

READ MORE

12

Sep 2026

Neoadjuvant atezolizumab addition quadruples pathological responses in resectable lung tumors

Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 months for patients receiving chemotherapy alone, according to final results from the Phase 3 IMpower030 trial.

READ MORE

12

Sep 2026

Low discontinuation rates confirm manageable safety of iza-bren

An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5 mg/kg dose for evaluation in the global Phase 3 IZABRIGHT-Lung01 registrational study.

READ MORE